Not found

Shiladitya Sengupta, PhD

Assistant Research Professor of Radiation Oncology, Institute for Academic Medicine
Assistant Research Member, Research Institute
Houston Methodist
Weill Cornell Medical College


Dr. Sengupta’s research interest during Ph.D. program was on studying the defects in DNA mismatch repair genes in the development of microsatellite instability in head and neck squamous cell carcinoma. During his post-doctoral training in Dr. Mitra’s group he worked on transcriptional regulatory aspects of mammalian AP-endonuclease (APE1/Ref-1), an essential DNA base excision repair (BER) protein. Dr. Mitra’s group initially discovered APE1’s N-terminal acetylation (AcAPE1) by histone acetyl transferase p300 at lysines 6 and 7 which modulates its transcriptional regulatory functions. His observations based on promoter ChIP-on-Chip/ChIP-sequencing and global gene Chip expression profile analyses showed APE1/AcAPE1’s involvement in the regulation of diverse set of gene expression in multitudes of pathways associated with tumorigenesis. He elucidated the novel role of APE1 and its acetylation in activating multidrug resistance gene MDR1 that controls tumor cell drug resistance, the repressor role of APE1 in regulation of renin gene that controls blood pressure homeostasis, and the dichotomous regulatory role of APE1 in cell cycle checkpoint gene CDKN1A/p21 regulationby both p53-dependent and independent mechanisms. At present, his interests are to (i) unravel the phenomenon of genome damage and repair during inducible gene activation through reactive oxygen species and (iii) explore BER at the context of chromatin organization particularly on the regulation of repair activities of DNA glycosylase NEIL1 and crosstalk with nucleosome assembly machineries during DNA damage, repair and replication.

Areas Of Expertise

Cell proliferation Drug resistance Transcription regulation Protein acetylation Genome damage response Genomic instability
Education & Training

, Jadavpur University
, University of Calcutta

Sustained inhibition of cMET-VEGFR2 signaling using liposome-mediated delivery increases efficacy and reduces toxicity in kidney cancer
Kulkarni, AA, Vijaykumar, VE, Natarajan, SK, Sengupta, S & Sabbisetti, VS 2016, Nanomedicine: Nanotechnology, Biology, and Medicine, vol 12, no. 7, pp. 1853-1861. DOI:

Algorithm for Designing Nanoscale Supramolecular Therapeutics with Increased Anticancer Efficacy
Kulkarni, A, Pandey, P, Rao, P, Mahmoud, A, Goldman, A, Sabbisetti, V, Parcha, S, Natarajan, SK, Chandrasekar, V, Dinulescu, D, Roy, S & Sengupta, S 2016, ACS Nano, vol 10, no. 9, pp. 8154-8168. DOI:

Rationally Designed 2-in-1 Nanoparticles Can Overcome Adaptive Resistance in Cancer
Goldman, A, Kulkarni, A, Kohandel, M, Pandey, P, Rao, P, Natarajan, SK, Sabbisetti, V & Sengupta, S 2016, ACS Nano, vol 10, no. 6, pp. 5823-5834. DOI:

Drug-induced reactive oxygen species (ROS) rely on cell membrane properties to exert anticancer effects
Molavian, HR, Goldman, A, Phipps, CJ, Kohandel, M, Wouters, BG, Sengupta, S & Sivaloganathan, S 2016, Scientific Reports, vol 6, 27439. DOI:

Scaffold attachment factor A (SAF-A) and Ku temporally regulate repair of radiation-induced clustered genome lesions
Hegde, ML, Dutta, A, Yang, C, Mantha, AK, Hegde, PM, Pandey, A, Sengupta, S, Yu, Y, Calsou, P, Chen, D, Lees-Miller, SP & Mitra, S 2016, Oncotarget. DOI:

Notch-Jagged signalling can give rise to clusters of cells exhibiting a hybrid epithelial/mesenchymal phenotype
Boareto, M, Jolly, MK, Goldman, A, Pietilä, M, Mani, SA, Sengupta, S, Ben-Jacob, E, Levine, H & Onuchic, JN 2016, Journal of the Royal Society Interface, vol 13, no. 118, 20151106. DOI:

Reporter nanoparticle that monitors its anticancer efficacy in real time
Kulkarni, A, Rao, P, Natarajan, S, Goldman, A, Sabbisetti, VS, Khater, Y, Korimerla, N, Chandrasekar, V, Mashelkar, RA & Sengupta, S 2016, Proceedings of the National Academy of Sciences of the United States of America, vol 113, no. 15, pp. E2104-E2113. DOI:

Regulation of limited N-terminal proteolysis of APE1 in tumor via acetylation and its role in cell proliferation
Bhakat, KK, Sengupta, S, Adeniyi, VF, Roychoudhury, S, Nath, S, Bellot, LJ, Feng, D, Mantha, AK, Sinha, M, Qiu, S & Luxon, BA 2016, Oncotarget. DOI:

Physical nanoscale conduit-mediated communication between tumour cells and the endothelium modulates endothelial phenotype
Connor, Y, Tekleab, S, Nandakumar, S, Walls, C, Tekleab, Y, Husain, A, Gadish, O, Sabbisetti, V, Kaushik, S, Sehrawat, S, Kulkarni, A, Dvorak, H, Zetter, B, R. Edelman, E & Sengupta, S 2015, Nature Communications, vol 6, 8671. DOI:

Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity
Majumder, B, Baraneedharan, U, Thiyagarajan, S, Radhakrishnan, P, Narasimhan, H, Dhandapani, M, Brijwani, N, Pinto, DD, Prasath, A, Shanthappa, BU, Thayakumar, A, Surendran, R, Babu, GK, Shenoy, AM, Kuriakose, MA, Bergthold, G, Horowitz, P, Loda, M, Beroukhim, R, Agarwal, S, Sengupta, S, Sundaram, M & Majumder, PK 2015, Nature Communications, vol 6, 6169. DOI:

Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition
Goldman, A, Majumder, B, Dhawan, A, Ravi, S, Goldman, D, Kohandel, M, Majumder, PK & Sengupta, S 2015, Nature Communications, vol 6, 6139. DOI:

Anti-platelet agents augment cisplatin nanoparticle cytotoxicity by enhancing tumor vasculature permeability and drug delivery
Pandey, A, Sarangi, S, Chien, K, Sengupta, P, Papa, AL, Basu, S & Sengupta, S 2014, Nanotechnology, vol 25, no. 44, 445101. DOI:

Sequential application of a cytotoxic nanoparticle and a PI3K inhibitor enhances antitumor efficacy
Pandey, A, Kulkarni, A, Roy, B, Goldman, A, Sarangi, S, Sengupta, P, Phipps, C, Kopparam, J, Oh, M, Basu, S, Kohandel, M & Sengupta, S 2014, Cancer Research, vol 74, no. 3, pp. 675-685. DOI:

PEGylated liposomal Gemcitabine: Insights into a potential breast cancer therapeutic
Papa, AL, Sidiqui, A, Balasubramanian, SUA, Sarangi, S, Luchette, M, Sengupta, S & Harfouche, R 2013, Cellular Oncology, vol 36, no. 6, pp. 449-457. DOI:

Supramolecular nanoparticles that target phosphoinositide-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy
Kulkarni, AA, Roy, B, Rao, PS, Wyant, GA, Mahmoud, A, Ramachandran, M, Sengupta, P, Goldman, A, Kotamraju, VR, Basu, S, Mashelkar, RA, Ruoslahti, E, Dinulescu, DM & Sengupta, S 2013, Cancer Research, vol 73, no. 23, pp. 6987-6997. DOI:

P2Y12 receptor inhibition augments cytotoxic effects of cisplatin in breast cancer
Sarangi, S, Pandey, A, Papa, AL, Sengupta, P, Kopparam, J, Dadwal, U, Basu, S & Sengupta, S 2013, Medical Oncology, vol 30, no. 2, 567. DOI:

Design principles for clinical efficacy of cancer nanomedicine: A look into the basics
Sengupta, S & Kulkarni, A 2013, ACS Nano, vol 7, no. 4, pp. 2878-2882. DOI:

Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells
Papa, AL, Basu, S, Sengupta, P, Banerjee, D, Sengupta, S & Harfouche, R 2012, BMC Cancer, vol 12, 419. DOI:

Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity
Sengupta, P, Basu, S, Soni, S, Pandey, A, Roy, B, Oh, MS, Chin, KT, Paraskar, AS, Sarangi, S, Connor, Y, Sabbisetti, VS, Kopparam, J, Kulkarni, A, Muto, K, Amarasiriwardena, C, Jayawardene, I, Lupoli, N, Dinulescu, DM, Bonventre, JV, Mashelkar, RA & Sengupta, S 2012, Proceedings of the National Academy of Sciences of the United States of America, vol 109, no. 28, pp. 11294-11299. DOI:

Rationally designed oxaliplatin-nanoparticle for enhanced antitumor efficacy
Paraskar, A, Soni, S, Roy, B, Papa, AL & Sengupta, S 2012, Nanotechnology, vol 23, no. 7, 075103. DOI: